bio

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum Seven…

6 days ago

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

April 27, 2026 17:00 ET  | Source: Cabaletta Bio PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq:…

1 week ago

Laigo Bio completes final close of oversubscribed seed financing of 17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs

Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a…

1 month ago

Avid Organics to Launch the World’s First Commercial-Scale Bio-Based Glycolic Acid, AviGa Bio HP70, at in-cosmetics Global in Paris

AviGa™ Bio HP70 is a bio-based, 70% cosmetic-grade glycolic acid available globally from April 14, 2026, with REACH registration ensuring…

2 months ago

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

March 17, 2026 22:46 ET  | Source: SAB Biotherapeutics, Inc. MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc.…

2 months ago

Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit

LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today…

2 months ago

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

February 23, 2026 17:10 ET  | Source: Kyntra Bio FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen…

2 months ago

Precise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine…

3 months ago

Defeating the “Cold Chain” Barrier: Bio Usawa and Nanoly Bioscience Announce Strategic $500 Million Licensing Agreement for Breakthrough DynaShield Technology

SAN FRANCISCO and LOS ANGELES and KIGALI, Rwanda, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bio Usawa, a leader in expanding…

3 months ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

February 11, 2026 06:00 ET  | Source: Upstream Bio – Verekitug provided statistically significant and clinically meaningful reductions in annualized…

3 months ago